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Objective. This study estimated the excess clinical, humanistic, and economic burden associated with depression among workingage adults with Rheumatoid Arthritis (RA). Methods. A retrospective cross-sectional study was conducted among working-age
(18 to 64 years) RA patients with depression (𝑁 = 647) and without depression (𝑁 = 2,015) using data from the nationally
representative Medical Expenditure Panel Survey for the years 2009, 2011, 2013, and 2015. Results. Overall, 25.8% had depression.
In adjusted analyses, adults with RA and depression compared to those without depression were significantly more likely to have
pain interference with normal work (severe pain: AOR = 2.22; 95% CI = 1.55, 3.18), functional limitations (AOR = 2.17; 95% CI
= 1.61, 2.94), and lower mental health HRQoL scores. Adults with RA and depression had significantly higher annual healthcare
expenditures ($14,752 versus 10,541, 𝑝 < .001) and out-of-pocket spending burden. Adults with RA and depression were more
likely to be unemployed and among employed adults, those with depression had a significantly higher number of missed work days
annually and higher lost annual wages due to missed work days. Conclusions. This study highlights the importance of effectively
managing depression in routine clinical practice of RA patients to reduce pain and functional limitations, improve quality of life,
and lower direct and indirect healthcare costs.

1. Introduction
Rheumatoid Arthritis (RA) is one of the most debilitating
chronic conditions, with the onset often occurring during the
prime working years of lives, between the ages of 20 and 40
years [1]. Individuals with RA experience substantial pain and
RA causes permanent work disability in more than one-third
of affected patients within 10 years of onset [2]. Such pain
and disabilities associated with RA may contribute to a higher
prevalence of depression in individuals with RA compared
to healthy controls [3]. An expert review of depression in
arthritis reported that the prevalence of depression in adults
with RA can be as high as 66.2% [4]. A systematic review and
meta-analysis of 72 studies estimated the prevalence rate to
be 16.8% [5].
The disease burden of depression in RA can be substantial
because depression can worsen survival [6] and increase

morbidity in terms of disability, health-related quality of life
(HRQoL), RA disease activity [7], and pain [8]. Depression in
RA can also increase healthcare resource utilization [9, 10],
which can lead to high health care expenditures for both
insurance payers, patients and families. As depression in
RA can aggravate disability, an individual may also suffer
economic losses due to work inability or even experience
economic losses due to missed work days. Although not
specific to RA, one study estimated that 6.9 million workingage adults reported arthritis-attributable work limitation [11].
One can speculate that depression can worsen the work
limitation because the presence of depression along with any
chronic physical condition more than doubles the likelihood
of work absenteeism as compared to the presence of any
chronic physical condition without depression [12].
However, to date, no published study in the US has done
a comprehensive analysis of the humanistic and economic
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Total number of non-institutionalized civilian individuals pooled
from the MEPS sample for the year 2009, 2011, 2013 and 2015
n = 144,559
Working-age adults aged between 18 and 64 years
n = 86,895

Working-age adults who did not die during the calendar year
n = 86,801
Working-age adults with a diagnosis of RA who did not die
during the calendar year
n = 2,662
Weighted N = 1,430,000 (≈1.4 million)

Working-age adults with RA and depression
n = 2,662
Weighted N = 369,136

Working-age adults with RA only
n = 2,015
Weighted N = 1,060,864

Figure 1: Flow diagram of study sample.

burden associated with depression among RA patients, particularly among working-age adults. In fact, a recent review
highlighted the significant knowledge gap in estimating
the disease burden of depression in adults with arthritis
[4]. Although there has been a handful of studies on the
association between depression and HRQoL among adults
with RA, most of these studies have been conducted outside
the US [13, 14] or only among women in a specific setting [15].
One US study used a cross-sectional design and examined
the relationship between depression and disability, HRQoL
in the US with data from the 2011 Behavioral Risk Factor
Surveillance System [16]. However, this study included all
forms of arthritis and did not focus on RA. Again, only one
study using 2006 commercial claims data in the US found
that RA patients with depression had a significantly higher
adjusted annual healthcare costs as compared to RA patients
without depression ($12,225 versus $11,404) [9]. However,
this study was based on commercially insured RA patients
and may not be representative of the US national population. Furthermore, this commercial insurance data did not
include certain patient characteristics which are important
confounders of healthcare costs such as race, education, and
income level.
Therefore, the objective of this study is to examine the
incremental burden of depression on the clinical, humanistic,
and economic outcomes among working-age adults with RA.

2. Methods
2.1. Study Design. A retrospective cross-sectional study
design with data from a nationally representative sample of
working-age adults (18–64 years) was used.
2.2. Data Source. We used data from the Medical Expenditure Panel Survey (MEPS), an annual household survey

of the noninstitutionalized civilian population in the US.
Information on demographic characteristics, medical conditions, health status, utilization of health care services, charges
and payments, access to care, health insurance coverage,
income, education, employment, and missed workdays of the
participants in the survey were extracted from the household
component of MEPS. We pooled four years of data (2009,
2011, 2013, and 2015) to have sufficient sample size and used
data from alternate years to avoid including two observations
per individual. Furthermore, a question related to the type
of arthritis was available in these years. MEPS recommends
pooling of data to increase sample size and it is a common
practice in published literature with MEPS data [17].
2.3. Study Sample. The study sample (𝑁 = 2,662) consisted
of working-age (18–64 years) who were diagnosed with RA
and who were alive during the study period (2009, 2011, 2013,
and 2015) (Figure 1). RA was identified from the priority
condition enumeration section. In this section, respondents
were queried whether an individual in the household has
ever been told by a doctor or another health professional
that she/he had arthritis and type of arthritis (RA versus
osteoarthritis). We also identified RA from medical condition file with the clinical classification code (202). Medical
conditions were reported by the respondents if they sought
treatment for the condition, or if the condition resulted in
disability, or if the condition was bothersome. The responses
were recorded as texts, and these texts were translated into
International Classification of Diseases, 9th Edition, Clinical
Modification (ICD-9-CM) codes by professional coders. In
addition, MEPS data provides clinical classification codes,
which are aggregated ICD-9-CM codes into clinically meaningful categories that group similar conditions (Agency for
Healthcare Research and Quality).
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2.4. Conceptual Framework. The conceptual framework for
this study was adapted from the Andersen’s Expanded Behavioral Model which posits that health services utilization and
outcomes of an individual are a function of predisposing
factors (e.g., age, sex, and race), enabling factors (e.g.,
marital status, education and poverty status), need factors
(e.g., chronic conditions, health status), and personal health
practices (e.g., physical activity, obesity, and smoking) [18].
2.5. Measures
2.5.1. Clinical Outcomes
Pain Interference with Normal Activities. Based on a selfadministered single-item question, pain interference with
normal activities during the past four weeks among the
household respondents was measured. The answers were
recorded on a 5-point Likert scale during the past 4 weeks. In
MEPS, pain was reported on a 5-point scale: (1) not at all, (2) a
little bit, (3) moderately, (4) quite a bit, and (5) extremely. For
purposes of this study we group pain categories as follows:
(1) not at all/little bit; (2) moderate; (3) severe (quite a
bit/extremely). Self-reported pain from MEPS has been used
in published literature to estimate the cost of pain [19]. There
were 42 individuals (5.9%) in the depression group and 140
individuals (6.6%) in the no depression group with missing
data on pain inference variable. These individuals were not
included in the analysis.
Any Functional Limitations. This variable summarizes
whether an individual had any limitations in instrumental
activities of daily living (IADL) (e.g., shopping, cooking,
using phone, paying bills, taking medications, driving, doing
laundry, or going shopping), activities of daily living (ADL)
(e.g., bathing, dressing, grooming, mouthcare, toileting,
and eating), functional limitations (walking, climbing stairs,
grasping objects, reaching overhead, lifting, bending or
stooping, or standing for long periods of time), or activity
limitations (work, housework, or school).
2.5.2. Humanistic Outcome: Health-Related Quality of Life.
HRQoL was measured by the generic Short-Form-12 Version
2 (SF12-V2) summary scores. The SF12-V2 is a generic multipurpose survey with 12 questions, which encompass eight
domains (role physical, role emotional, physical function,
social function, mental health, vitality, pain, and general
health). These questions are designed to provide summary
measures of overall HRQoL of an individual. The Mental Component Summary (MCS) score was derived from
the responses to the items in the domains: vitality, social
functioning, role emotional (limitations in work and daily
activities because of emotional problems), and mental health.
The Physical Component Summary (PCS) score was derived
from the responses to the items in the domains: physical
functioning, role physical, bodily pain, and general health.
Both MCS and PCS scores ranged from 0 to 100, with higher
scores representing better self-reported health and better
HRQoL related to mental or physical health [20].
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2.5.3. Economic Outcomes: Direct Healthcare Expenditures
Total Healthcare Expenditures. In the MEPS, expenditures
are defined as the sum of direct payments for care provided
during the year. The direct payments include twelve sources
of payment categories such as out-of-pocket by patient or
families, Medicare, Medicaid, Private Insurance, Veteran
Administration, worker’s compensation, and others. Total
annual per person healthcare expenditures were calculated
as the sum of inpatient, outpatient, emergency, dental, home
health, vision, prescription drugs, and other medical supplies.
All expenditures were inflation adjusted to 2015 US dollars
(USD) using consumer price index for medical services from
the bureau of medical services.
Total Out-of-Pocket Spending Burden by Patients and Families. We also estimated the total out-of-pocket spending on
healthcare by the respondent and/or family. These included
annual deductibles, copayment, and coinsurance for services
and payment for services that were not covered by health
insurance. We calculated out-of-pocket spending burden
as the ratio of out-of-pocket healthcare expenditures to
personal income [21], which varied from zero to 100. Based
on published literature, we defined spending 10% or more
of personal income on health care as high out-of-pocket
spending burden [22].
2.5.4. Economic Outcomes: Indirect Healthcare Burden
Unemployment (i.e., Labor Market Outcome). In the MEPS,
employment section covers questions about each person’s
employment or self-employment status. Based on these questions, we classified individuals who were currently unemployed.
Missed work days were measured whether individuals lost
a half-day or more from work because of illness, injury, or
mental or emotional problems during the year and how many
workdays were lost. This was calculated only for employed
adults.
Lost wages for each individual were calculated by multiplying missed work days with an average daily wage of each
individual. All wages were adjusted to 2015 general consumer
inflation rates derived from the bureau of labor statistics.
Key Explanatory Variable
Depression (Yes/No). Depression was identified based on
the clinical classification code “657,” which included both
depressive disorders and bipolar disorders.
Other Explanatory Variables. Predisposing characteristics
were sex (male, female), race/ethnicity (Whites, AfricanAmerican, and other racial minorities), and age in years
(18–39, 40–49, and 50–64). Enabling factors comprised marital status (married, widow, separated/divorced, and never
married), family poverty status (not poor, poor), health
insurance status (public, private), and usual source of care
(yes, no). Need factors included having a chronic condition
other than RA from a list of eight conditions (asthma,
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cancer, chronic obstructive pulmonary disease, diabetes,
heart disease, hypertension, stroke, and thyroid), anxiety,
perceived physical health status (excellent/very good, good,
and fair/poor), and perceived mental health status (excellent/very good, good and fair/poor). Personal health practice
factors included obesity (obese and not obese), smoking
status (current smoker, others, and missing), and exercise
(“yes” and “no” exercise).
2.6. Statistical Analyses. A variety of statistical analyses were
used based on the measurement of the outcome variables. The
unadjusted relationships between the presence of depression
and categorical variables and outcomes (pain interference
with activities, employment, and OOP burden) were assessed
with chi-square tests. Unadjusted differences in continuous
outcomes (PCS, MCS, all-cause healthcare expenditures, and
out-of-pocket spending by the patients and their families)
by depression were tested with 𝑡-tests. Multinomial logistic
regression was used to analyze the association between
depression and pain-related interference with normal work
after adjusting for the predisposing, enabling, need, and
external environment characteristics. Logistic regression was
used to analyze the association between depression and
binary categorical variables (e.g., any limitations, unemployment, and out-of-pocket spending burden) after adjusting
for covariates. Adjusted models for continuous outcomes
(expenditures, out-of-pocket expenditures, and lost wages)
consisted of Generalized Linear Models (GLM). GLM is
flexible and can handle categorical outcomes, continuous
outcomes, and count-data with the appropriate distribution
family and a link function. For count-data (e.g., the number
of missed work days) we used negative binomial regression.
Counterfactual Prediction Technique (Recycled Prediction).
We used counterfactual recycled prediction, an approach that
is gaining attention [23, 24] to estimate excess total healthcare
expenditures, prescription expenditures, missed work days,
and lost wages attributable to depression among working-age
adults with Rheumatoid Arthritis. The recycled prediction
technique is a preferred approach because it adjusts for
differences in characteristics between the depression and
no depression group by creating counterfactual scenarios.
In all recycled prediction models, confidence intervals were
obtained using 2000 bootstrap replications using the percentile method. To account for the complex design of MEPS,
we conducted all analyses using the survey procedures in
Statistical Analysis Software (SAS) version 9.3, Cary, NC,
USA, and the survey design features with STATA 14. As
we pooled four years, to get annualized weighted numbers, we divided the weights by four, recommended by the
MEPS investigators [25] and used in the published literature
[26].

3. Results
3.1. Description of the Study Sample. Majority of the study
sample was female (64%) and white (63%), aged between 50
and 64 years (61%), and had multimorbidity (72%). Only 26%
of individuals who perceived themselves having excellent
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or very good physical health and 44.8% reported having
excellent or very good mental health (see Table 1).
Overall, 25.8% of adults with RA reported depression
(Table 2). We observed significant differences in the rate of
depression by predisposing, enabling, need factors, and personal health practices except for age, education, and region.
For example, female adults with RA reported a significantly
higher rate of depression than their male counterparts (29.6%
versus 19.1%). The higher rate of depression was also observed
among individuals with multimorbidity (29.1% versus 17.4%).
A higher percentage of those who perceived themselves to
be poor/fair physical health reported depression compared to
those in excellent or very good health (38.0% versus 12.4%).
3.2. Clinical Outcomes
3.2.1. Pain Interference with Normal Activities. A higher
percentage of adults with RA and depression reported severe
pain interfering with work or other normal activities compared to those with RA and no depression (54.8% versus
30.8%) (Table 3). After adjusting for predisposing, enabling,
need, personal health practices, and external environment
factors, and adults with depression were 2.2 times as likely to
report severe pain interference with normal work activities
than those without depression (AOR = 2.22; 95% CI = 1.55,
3.18) (Table 3).
3.2.2. Any Functional Limitations. A significantly higher
percentage of adults with RA and depression reported any
functional limitations compared to those with RA and no
depression (79% versus 51.1%) (Table 3). After adjusting for
covariates adults with RA and depression were more than 2
times as likely to report any functional limitations (AOR =
2.24; 95% CI = 1.62, 3.10) (Table 3).
3.3. Humanistic Outcomes. Adults with RA and depression
reported significantly lower HRQoL scores in both Physical
Component Summary score (35.1 versus 40.2, 𝑝 < .001)
and Mental Component Summary score (37.2 versus 48.7,
𝑝 < .001) compared to adults with RA without depression
(Table 4). In adjusted analyses, a significant difference was
observed only in the mental domain of the HRQoL; the
presence of depression was associated with a decrement of
8.72 in MCS scores (Table 4). The counterfactual predictions
yielded similar differences in MCS (37.19 in adults with
depression versus 45.91 in adults without depression, 𝑝 <
.001). The relationship between depression and PCS scores
became insignificant after adjustment for the presence of
multiple chronic conditions.
3.4. Economic Outcomes
3.4.1. Direct Total Healthcare Expenditures. In unadjusted
analysis, adults with RA and depression had significantly
higher annual healthcare expenditures ($17,941 versus
$10,064 𝑝 < .001). In the adjusted GLM with gamma distribution and log-link, we found that depression was associated
with greater total healthcare expenditures compared to those
without depression (Beta = 0.34, SE = 0.08). When converted
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Table 1: Description of study sample. Working-age (18 to 64 years)
adults with Rheumatoid Arthritis Medical Expenditure Panel Survey
(2009, 2011, 2013, and 2015).

All
Gender
Female
Male
Race/ethnicity
White
African American
Latino
Others
Age in years
18–39 years
40–49 years
50–59 years
60–64 years
Marital status
Married
Widow/separated/divorced
Never married
Education
Less than high school
High school
More than high school
Poverty status
Poor
Not poor
Middle income
High income
Insurance status
Private
Public
Uninsured
Employment
Employed
Not employed
Region
Northeast
Midwest
South
West
Perceived physical health
Excellent/very good
Good
Fair/poor
Perceived mental health
Excellent/very good
Good
Fair/poor

𝑁

Weighted 𝑁

Weighted%

2,662

5,719,998

100.0

1,826
836

3,661,958
2,058,040

64.0
36.0

1,061
778
639
184

3,596,249
989,822
780,416
353,511

62.9
17.3
13.6
6.2

444
609
1,080
529

956,652
1,271,670
2,326,292
1,165,384

16.7
22.2
40.7
20.4

1,287
845
530

3,098,420
1,630,180
991,398

54.2
28.5
17.3

665
939
1,036

1,007,827
2,043,963
2,623,400

17.6
35.7
45.9

740
675
708
539

1,216,767
1,204,168
1,670,010
1,629,054

21.3
21.1
29.2
28.5

1,302
932
428

3,411,533
1,580,322
728,144

59.6
27.6
12.7

1,309
1,352

3,071,100
2,647,283

53.7
46.3

383
523
1,190
566

984,779
1,264,228
2,454,395
1,016,597

17.2
22.1
42.9
17.8

607
871
1,184

1,488,614
2,001,187
2,230,197

26.0
35.0
39.0

607
871
1184

1,488,614
2,001,187
2,230,197

26.0
35.0
39.0

Table 1: Continued.
Multimorbidity
RA only
Multimorbidity
Anxiety
Yes
No
Obesity
Obese
Not obese
Smoking status
Current smoker
Others
Missing
Exercise
Yes
No

𝑁

Weighted 𝑁

Weighted%

716
1,946

1,605,886
4,114,112

28.1
71.9

494
2,168

1,134,341
4,585,657

19.8
80.2

1,218
1,392

2,521,340
3,084,702

44.1
53.9

698
1,755
209

1,567,457
3,729,925
422,616

27.4
65.2
7.4

1,077
1,568

2,364,802
3,321,567

41.3
58.1

Note. Based on 2,662 adults with Rheumatoid Arthritis, aged between 18
and 64 years, who were alive during the calendar year. Missing data for
the variables, education, obesity, smoking, and exercise, are not presented.
Weighted 𝑁 and percentages were derived by dividing the person weights by
the number of years pooled.

to original dollars this represented $14,752 for those with
depression and $10,541 for those without depression
(Table 5). Estimates from counter-factual recycled prediction
revealed that depression was associated with an excess of
$4,212 total healthcare expenditures with 95% CI = $4,114,
$4,318.
In unadjusted analysis, patients/families in the RA +
depression group spent significantly higher amounts out-ofpocket on health care compared to the RA + no depression
group ($1,443 versus $1,052, 𝑝 < .001). In the adjusted
GLM with gamma distribution and log-link, we found that
depression was associated with greater total out-of-pocket
healthcare spending compared to those without depression
(Beta = 0.23, SE = 0.06). When converted to original dollars
this represented $1,232 for those with depression and $979 for
those without depression (Table 5). Estimates from counterfactual recycled prediction revealed that depression was
associated with an excess of $253 with 95% CI = $247, 260.
When high out-of-pocket spending burden was measured as spending greater than 10% of income on healthcare,
we found that 30.7% of adults with depression and 21.3% of
adults without depression had high out-of-pocket spending
burden. After adjusting for other factors, adults with depression were significantly more likely to have high out-of-pocket
spending burden (AOR = 1.34; 95% CI = 1.01, 1.79).
3.4.2. Indirect Economic Burden
Labor Market Outcome (Unemployment), Missed Work Days,
and Lost Wages. Presence of depression was significantly
associated with unemployment among adults with RA; 64.1%
of adults with depression were unemployed compared to
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Table 2: Description of study sample by depression among working-age (18–64 years) adults with Rheumatoid Arthritis Medical Expenditure
Panel Survey (2009, 2011, 2013, and 2015).

All
Gender
Female
Male
Race/ethnicity
White
African American
Latino
Others
Age in years
18–39 years
40–49 years
50–59 years
60–64 years
Marital status
Married
Widow/separated/divorced
Never married
Education
Less than high school
High school
Missing
Poverty status
Poor
Not poor
Middle income
High income
Insurance status
Private
Public
Uninsured
Employment
Employed
Not employed
Region
Northeast
Midwest
South
West
Perceived physical health status
Excellent/very good
Good
Fair/poor
Perceived mental health status
Excellent/very good
Good
Fair/poor
Multimorbidity
RA only
Multimorbidity

𝑁
647

RA with depression
Wt. 𝑁
Wt. Row%
369,136

𝑁
2,015

RA without depression
Wt. 𝑁
Wt. Row%
1,060,864

Sig
∗∗∗

502
145

270,895
98,241

29.6
19.1

1,324
691

644,595
416,269

70.4
80.9

328
157
127
35

264,578
45,643
40,938
17,977

29.4
18.4
21
20.3

733
621
512
149

634,485
201,813
154,166
70,400

70.6
81.6
79
79.7

98
149
281
119

58,925
82,063
156,442
71,706

24.6
25.8
26.9
24.6

346
460
799
410

180,238
235,855
425,131
219,640

75.4
74.2
73.1
75.4

248
259
140

160,488
139,902
68,746

20.7
34.3
27.7

1,039
586
390

614,118
267,643
179,104

79.3
65.7
72.3

170
232
4

65,953
138,615
2,236

26.2
27.1
20

495
707
18

186,004
372,376
8,966

73.8
72.9
80

236
185
141
85

103,612
88,172
101,112
76,241

34.1
29.3
24.2
18.7

504
490
567
454

200,580
212,870
316,391
331,023

65.9
70.7
75.8
81.3

∗∗∗

∗∗∗

∗∗∗

∗∗∗
235
345
67

183,245
153,607
32,284

21.5
38.9
17.7

1,067
587
361

669,638
241,474
149,752

78.5
61.1
82.3

195
452

132,391
236,745

17.2
35.8

1,114
900

635,384
425,076

82.8
64.2

89
157
271
130

50,671
93,289
161,001
64,175

20.6
29.5
26.2
25.3

294
366
919
436

195,524
222,768
452,598
189,975

79.4
70.5
73.8
74.7

72
165
410

46,019
110,972
212,145

12.4
22.2
38

535
706
774

326,135
389,325
345,405

87.6
77.8
62

113
207
327

74,855
122,356
171,925

11.7
25.1
56.9

995
730
290

565,345
365,098
130,422

88.3
74.9
43.1

110
537

69,703
299,433

17.4
29.1

606
1,409

331,768
729,096

82.6
70.9

∗∗∗

∗∗∗

∗∗∗

∗∗∗
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Table 2: Continued.
𝑁

RA with depression
Wt. 𝑁
Wt. Row%

𝑁

RA without depression
Wt. 𝑁
Wt. Row%

Sig
∗∗∗

Anxiety
Yes
No
Obesity
Obese
Not obese
Smoking status
Current smoker
Others
Exercise
Yes
No exercise

259
388

150,809
218,327

53.2
19

235
1,780

132,776
928,088

46.8
81
∗∗

353
287

190,757
172,382

30.3
22.4

865
1,105

439,579
598,794

69.7
77.6

250
355

142,876
204,588

36.5
21.9

448
1,400

248,988
727,893

63.5
78.1

190
454

106,306
259,932

18
31.3

887
1,114

484,895
570,460

82
68.7

∗∗∗

∗∗∗

Note. Based on 2,662 adults with Rheumatoid Arthritis aged between 18 to 64 years, who were alive during the calendar year. Missing data for the variables,
education, obesity, smoking, and exercise, are not presented. Asterisks represent significant group differences by the presence of depression based on chi-square
tests. Weighted 𝑁 and percentages were derived by dividing the person weights by the number of years pooled; Wt.: weighted; ∗∗∗ 𝑝 < .001; .001 ≤ ∗∗ 𝑝 < .01.

Table 3: Clinical outcome associated with depression among working-age adults with Rheumatoid Arthritis Medical Expenditure Panel
Survey (2009, 2011, 2013, and 2015).
RA + depression
𝑁
All

Wt.
col%

605

Pain interference with daily activity
Mild/none
Moderate
Severe (extreme/quite a lot)
Limitations
Any functional limitations

RA and no depression
Wt.
𝑁
col%
1,875

∗∗∗
155
92
358

29.8
15.4
54.8

918
317
640

51.9
17.3
30.8

528

79.0

1,026

51.1

Adjusted odds ratio and 95% CI for depression from multinomial logistic regression on pain interference with normal activity
AOR
95% CI
Pain interference with daily activity
Mild/none (reference group)
Moderate
Severe

1.37
2.22

[0.91, 2.06]
[1.55, 3.18]

Adjusted odds ratio and 95% CI for depression from logistic regression on limitations
AOR
95% CI
Limitations
Any functional limitations

Sig

2.24

[1.62, 3.10]

∗∗∗
Sig

∗∗∗
Sig
∗∗∗

Note. Based on 2,662 adults with Rheumatoid Arthritis aged between 18 and 64 years, who were alive during the calendar year. Adjusted multinomial logistic
regression controlled sex, race/ethnicity, age, region, marital status, education, family poverty status, health insurance, physical health status, mental health
status, anxiety, multimorbidity, obesity, physical activity, and smoking. Asterisks represent significant group differences by the presence of depression; ∗∗∗ 𝑝 <
.001; ADL: activities of daily living; Col: column; IADL: instrumental activities of daily living; Wt.: weighted.

40.1% adults without depression. Even after controlling for
other factors mentioned in the methods section, adults with
RA and depression were 1.55 times as likely as those without
depression to be unemployed (AOR = 1.55; 95% CI = 1.14,
2.10). Among employed adults, those with depression had
significantly higher number of missed work days annually (9
versus 6, 𝑝 < .05) and higher lost wages ($813 versus $571,

𝑝 < .05) due to missed work (Table 5). We obtained similar
results with counterfactual recycled predictions.

4. Discussion
In this study using a nationally representative sample of
community-dwelling US adults, one in four working-age
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Table 4: Humanistic outcomes (health-related quality of measures) by presence of depression among working-age adults with Rheumatoid
Arthritis Medical Expenditure Panel Survey (2009, 2011, 2013, and 2015).
RA + depression
Wt. mean
All

RA and no depression
Wt. mean
SE

SE

𝑁 = 647

Sig

𝑁 = 2,015

Physical component summary score
35.07
0.89
40.18
0.47
∗∗∗
Mental component summary
37.20
0.77
48.74
0.37
∗∗∗
score
Fully adjusted model: parameter estimates and standard errors for depression ordinary least squares regression mental component
summary score
Beta
Standard error
Sig
Depression
−8.72
0.81
No depression (reference group)
Fully adjusted model: parameter estimates and standard errors for depression ordinary least squares regression physical
component summary score
Beta
Standard error
Depression
No depression (reference group)

−1.29

∗∗∗

Sig

0.81

Note. Based on 2,662 adults with Rheumatoid Arthritis aged between 18 and 64 years, who were alive during the calendar year. Asterisks represent significant
group differences by the presence of depression. The ordinary least squares regressions controlled for the following variables: sex, race/ethnicity, age, region,
marital status, education, family poverty status, health insurance, anxiety, multimorbidity, obesity, physical activity, and smoking; SE: standard error; Wt.:
weighted; ∗∗∗ 𝑝 < .001.

adults with RA reported depression. This rate is considerably
higher compared to the 6.8% rate of depression in the
general population in the US [27] and higher than the
pooled depression rate of 16.8% reported by Matcham and
colleagues in a meta-analysis of 72 studies that included 13,189
RA patients [5]. The same meta-analysis also reported the
presence of depressive symptoms in 38.8% of RA patients
measured using Patient Health Questionnaire (PHQ-9) and
34.2% of RA patients measured using Hospital Anxiety and
Depression Scale (HADS) [5]. Therefore, the differences in
the rate of depression in RA patients can be explained by the
differences in the instruments used to identify depression.
Our study findings indicated the substantial additional
clinical burden imposed by depression in working-age adults
with RA. These findings have implications for comanagement
of depression and RA. Although not specific to RA, a
randomized clinical trial of 1,001 patients with concurrent
depression and arthritis and seeking care from 18 primary
care clinics [28] suggested that collaborative depression care
not only reduced depressive symptoms but also improved
arthritis related outcomes, such as decreasing pain and
functional limitations. There is some evidence that diseasemodifying drugs used to treat RA can have spill-over effects
in reducing depressive symptoms. For example, depression
levels decreased significantly following commencement and
continuity of rituximab, a B cell-directed therapy, among
individuals with RA [29]. Therefore, future studies need
to systematically evaluate whether antirheumatic treatment
among individuals with RA can help alleviate depressive
symptoms.
We also observed significant decrements in HRQoL
measures, specifically the MCS scores. This is not surprising;
however, it is important given the strong association between

patient-reported outcomes and disease activity [30]. It has
also been suggested that patient-reported outcomes such as
the HRQoL and other measures in clinical trials and routine
clinical practice may shed light on variations in treatment
response as well as the burden of disease among RA adults
[30, 31]. Our findings suggest that collecting patient-reported
HRQoL can be critical in assessing disease burden that may
not be captured by clinical assessment alone [30].
Depression in working-age adults with RA was associated
with substantial direct and indirect economic burden. For
example, the presence of depression more than doubled the
annual per person total healthcare costs, a number of missed
work days, and lost wages due to missed work days, even after
controlling for predisposing factors, enabling characteristics,
need factors, and personal health care practices. Although
published evidence on the incremental economic impact
of depression in RA is limited [9], our findings which are
consistent with studies assessing the burden of depression
on other chronic illnesses such as diabetes, cardiovascular
disease, and asthma have also reported the synergistic effect
of depression in increasing the economic burden among
individuals with chronic conditions [12, 32].
Our findings on the economic burden of depression in
RA patients have important implications for the payers as it
highlights an opportunity for reducing expenditures in RA
patients by increasing efforts towards screening and effectively treating depression in RA patients. Potential strategies
could be improving the integration of mental health services
with rheumatology practice and facilitating mental health
training for rheumatologists. Future studies need to explore
whether treatment for depression provides an opportunity
to reduce direct healthcare expenditures associated with
depression in RA patients.
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Table 5: Economic outcomes by presence of depression among working-age adults with Rheumatoid Arthritis Medical Expenditure Panel
Survey (2009, 2011, 2013, and 2015).
RA + depression
Wt. mean

SE

𝑁 = 647

All
Total healthcare expenditures (2015 $)
Total out-of-pocket spending by
patients/families (2015 $)

RA and no depression
Wt. mean
SE

Sig

𝑁 = 2,015

17,941

1489

10,064

574

∗∗∗

$1,443

135

$1,052

73

∗∗∗

Adjusted total direct healthcare expenditures of depression from generalized linear models with gamma distribution and log link
Wt. mean
95% CI
Wt. mean
95% CI

Sig
∗∗∗

Total healthcare expenditures (2015 $)
Total out-of-pocket spending by
patients/families (2015 $)

14,752

(14,411–15,125)

10,541

(10,206–10,806)

1,232

(1,202–1265)

979

(955–1,005)

∗∗∗

Incremental total direct healthcare expenditures of depression from counterfactual recycled prediction
Wt. mean
95% CI
Total healthcare expenditures (2015 $)
Total out-of-pocket spending by
patients/their families (2015 $)

4,212

(4,114, 4318)

∗∗∗

253

(247–260)

∗∗∗

High out-of-pocket spending burden (>10% income spent on healthcare)
RA + depression
RA and no depression
𝑁
Wt. col%
𝑁
Wt. col%
High out-of-pocket spending burden
192
30.7
424
21.3
∗∗∗
Fully adjusted model: adjusted odds ratio (AOR) and 95% confidence intervals (CI) of Depression from logistic regression on high
out-of-pocket burden
AOR
95% CI
Sig
Depression
No depression (reference)

1.34

[1.01, 1.79]

Unemployment among working-age adults
RA + depression
𝑁
Wt. col%

∗∗

RA and no depression
𝑁
Wt. col%

Unemployed
452
64.1
900
40.1
Fully adjusted model: adjusted odds ratio (AOR) and 95% confidence intervals (CI) of depression from logistic regression on
unemployment
AOR
95% CI
Sig
Depression
No depression (reference)

1.55

[1.14, 2.10]

∗∗∗

∗∗∗

Fully adjusted models: total productivity losses by depression from negative binomial regression on missed work Days
Wt. mean
95% CI
Wt. mean
95% CI

Sig
∗∗∗

Number of missed work days
Lost wages

9.0
853

(8.7–9.4)
(833–873)

6.0
571

(5.7–6.2)
(558–584)

∗∗∗

Incremental total productivity losses associated with depression from counterfactual recycled prediction
Wt. mean
95% CI
Number of missed work days
Lost wages

3.1
282

(2.9–3.2)
(276–289)

∗
∗

Note. Based on 2,662 adults with Rheumatoid Arthritis aged between 18 and 64 years, who were alive during the calendar year. Asterisks represent significant
group differences by the presence of depression. The adjusted models squares regressions controlled for the following variables: sex, race/ethnicity, age, region,
marital status, education, family poverty status, health insurance, physical health, mental health status, anxiety, multimorbidity, obesity, physical activity, and
smoking. Missed work days and lost wages were estimated only for those who were employed; ∗∗∗ 𝑝 < .001; .001 ≤ ∗∗ 𝑝 < .01; .01 ≤ ∗ 𝑝 < .05.
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The study findings have important implications for the
employers because depression costs US employers more than
$31 billion annually due to missed work and decreased
work performance [33]. One study done in the US reported
that depression leads to the highest reduction in work
performance and the highest employer burden relative to
any other chronic conditions [34]. Strategies that employers
may adopt to improve mental health in employees include
organizing workplace health promotion programs and stress
management projects, which have shown the benefits of
prevention and management of depression in workplace [35,
36].
To the best of our knowledge, this is the first populationbased study that comprehensively examined the excess
clinical, humanistic, and economic burden of depression
in working-age adults with RA. Other strengths of this
study include the use of nationally representative survey,
adjustment of a comprehensive list of confounders such
as predisposing factors, enabling factors, need factors, and
personal health care practices and the use of robust statistical
techniques such as GLM, and recycled prediction in estimating the incremental costs and missed workdays.
However, the findings of this study should be interpreted
considering its potential limitations. First, we did not control
for the severity and duration of RA and depression as MEPS
does not contain this information. These factors can be
important confounders of both healthcare costs and work
absence. Second, we have measured productivity loss as
missed work days and did not consider other kinds of
productivity loss such as reduced productivity while at work
(presenteeism) and loss of employment.
Our findings would provide valuable insights to payers and other decision-makers to better understand the
economic impact of comorbid depression on working RA
patients from US societal perspective. It is well-documented
that depression in RA patients is often underrecognized and
undertreated in routine clinical practice [37, 38]. Therefore,
our study underscores the need for incorporating depression
screening and management in the routine clinical management of RA in order to offset the substantial incremental
costs associated with depression. Published evidence has
well documented that depression is a treatable condition.
However, it is still not clear whether depression treatment is
equally effective in RA patients as compared to those with
depression without RA [39]. Future studies need to assess the
potential cost reductions that can be achieved through early
detection and more aggressive treatment of depression in RA
patients.
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